Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

Inclusion Criteria: * Patients with pathologically confirmed diagnosis of aggressive CD20(+) B-NHL, * including DLBCL and MCL. * Stage II, III or IV by Ann Arbor Classification. * Superficially accessible lesion for core-needle biopsy, e.g. cervical, axillary, * inguinal, subcutaneous. * Disease that has progressed (clinically or radiographically) after standard-of-care * prior therapy, including anthracycline-based therapy for DLBCL and anti-CD20 * mAb-based therapy for all histologies. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from study entry: * Contraindication to any of the individual components of glofitamab or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products * Any prior treatment with a BsAb targeting CD3 and CD20 * Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation * Prior treatment with systemic immunotherapeutic agents, including but not limited to, radio-immuno-conjugates, antibody-drug conjugates, immune/cytokines and monoclonal antibodies (mAbs) (e.g., anti-cytotoxic T lymphocyte associated protein 4, anti-PD-1, and anti-PD-L1) within 4 weeks or five half-lives of the drug, whichever is shorter * Treatment with CAR-T therapy within 30 days prior to first dose of glofitamab * Any investigational therapy for the purposes of treating cancer within 28 days prior to the start of Cycle 1 …